The US kratom industry sees the short period the Food and Drug Administration allowed for comments on whether kratom should be added to the United Nations’ schedule of controlled substances as another example of the agency’s refusal to consider the botanical’s safety and benefits.
The American Kratom Association didn’t convince a federal judge on 9 August to order the FDA to extend from that day to 31 August a deadline for comments responding to World Health Organization’s request for information on whether kratom constituent ingredients mitragynine and 7-hydroxymitragynine should be deemed controlled substances under the UN’s s 1971 Convention on Psychotropic Substances
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?